What is NDC 16729-230?

16729-230 is the product NDC for Pemetrexed, Pemetrexed disodium hemipentahydrate 500 mg/20mL injection, powder, lyophilized, for solution, listed with the FDA by Accord Healthcare Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

What is the active ingredient?

Pemetrexed disodium hemipentahydrate.

Accord Healthcare Inc., NDC labeler code 16729. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Pemetrexed?

57 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Pemetrexed NDC 16729-230 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)16729-230Labeler and product segments. Claims need a package NDC.

Product NDC at billing width16729-0230Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
16729-230-11	1672902301116729023011	1 VIAL in 1 CARTON (16729-230-11) / 20 mL in 1 VIALMarketed from May 25, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pemetrexed
Generic name (nonproprietary): pemetrexed
Active ingredients: Pemetrexed disodium hemipentahydrate — 500 mg/20mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: Accord Healthcare Inc.NDC labeler code 16729
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 203485
Marketing start: May 25, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Folic Acid Metabolism Inhibitors (Mechanism)
Identifiers: Product ID 16729-230_1d874430-c6ce-cff2-e063-6394a90a4a49SPL ID 1d874430-c6ce-cff2-e063-6394a90a4a49SPL set ID dfd19e67-54cb-c062-e053-2995a90a294aRxCUI 1728072, 1728077, 2601728UNII F4GSH45R4CUPC 0316729229036, 0316729244381, 0316729230117
Pharmacologic class: Folate Analog Metabolic Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N416729023011 followed by a unit qualifier and the quantity

Package 16729-0230-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 18, 2024.

Indications (excerpt from the label)

Pemetrexed for injection is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, meta…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 16729-230

What is NDC 16729-230?: 16729-230 is the product NDC for Pemetrexed, Pemetrexed disodium hemipentahydrate 500 mg/20mL injection, powder, lyophilized, for solution, listed with the FDA by Accord Healthcare Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Pemetrexed.
What is the active ingredient?: Pemetrexed disodium hemipentahydrate.
Who is the labeler?: Accord Healthcare Inc., NDC labeler code 16729. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Pemetrexed?: 57 other product NDCs are listed under this name. See all Pemetrexed NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Pemetrexed NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Pemetrexedpemetrexed disodium	Pemetrexed disodium heptahydrate 100 mg/4mL	Injection, Powder, Lyophilized, For solutionIntravenous	Somerset Therapeutics LLC	70069-834	70069-0834-01
Pemetrexedpemetrexed disodium	Pemetrexed disodium heptahydrate 500 mg/20mL	Injection, Powder, Lyophilized, For solutionIntravenous	Somerset Therapeutics LLC	70069-835	70069-0835-01
Pemetrexedpemetrexed disodium	Pemetrexed disodium hemipentahydrate 100 mg/4.2mL	Injection, Powder, Lyophilized, For solutionIntravenous	Sagent Pharmaceuticals	25021-260	25021-0260-10
Pemetrexedpemetrexed disodium	Pemetrexed disodium hemipentahydrate 500 mg/20mL	Injection, Powder, Lyophilized, For solutionIntravenous	Sagent Pharmaceuticals	25021-261	25021-0261-50
Pemetrexedpemetrexed disodium	Pemetrexed disodium hemipentahydrate 100 mg/10mL	Injection, Powder, Lyophilized, For solutionIntravenous	NorthStar RxLLC	72603-325	72603-0325-01
Pemetrexedpemetrexed disodium	Pemetrexed disodium hemipentahydrate 500 mg/50mL	Injection, Powder, Lyophilized, For solutionIntravenous	NorthStar RxLLC	72603-425	72603-0425-01
Pemetrexed	Pemetrexed disodium hemipentahydrate 100 mg/1	Injection, Powder, For solutionIntravenous	Solco Healthcare US, LLC	43547-632	43547-0632-01
Pemetrexedpemetrexed disodium	Pemetrexed disodium hemipentahydrate 100 mg/4mL	Injection, Powder, Lyophilized, For solutionIntravenous	Camber Pharmaceuticals, Inc.	31722-336	31722-0336-31
Pemetrexedpemetrexed disodium	Pemetrexed disodium hemipentahydrate 500 mg/20mL	Injection, Powder, Lyophilized, For solutionIntravenous	Camber Pharmaceuticals, Inc.	31722-337	31722-0337-31
Pemetrexedpemetrexed disodium	Pemetrexed disodium hemipentahydrate 100 mg/10mL	InjectionIntravenous	Shilpa Medicare Limited	63759-3048	63759-3048-01

All 58 Pemetrexed NDCs

Other NDCs under ANDA 203485

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 203485
Product	Strength	Form · route	Labeler	Product NDC
Pemetrexed	Pemetrexed disodium hemipentahydrate 100 mg/4mL	Injection, Powder, Lyophilized, For solutionIntravenous	Accord Healthcare Inc.	16729-229
Pemetrexed	Pemetrexed disodium hemipentahydrate 1 g/40mL	Injection, Powder, Lyophilized, For solutionIntravenous	Accord Healthcare Inc.	16729-244